Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity

The origins of preexisting SARS-CoV-2 cross-reactive antibodies and their potential impacts on vaccine efficacy have not been fully clarified. In this study, we demonstrated that S2 was the prevailing target of the preexisting S protein cross-reactive antibodies in both healthy human and SPF mice. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Liqiu, Weng, Shufeng, Wu, Jing, Tian, Xiangxiang, Zhang, Yifan, Wang, Xuyang, Wang, Jing, Yan, Dongmei, Wang, Wanhai, Fang, Fang, Zhu, Zhaoqin, Qiu, Chao, Zhang, Wenhong, Xu, Ying, Wan, Yanmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481142/
https://www.ncbi.nlm.nih.gov/pubmed/36100957
http://dx.doi.org/10.1080/19490976.2022.2117503

Ejemplares similares

Ejemplares similares